Jiangsu Kanion PharmaceuticalLtd Management
Management criteria checks 4/4
Jiangsu Kanion PharmaceuticalLtd's CEO is Yongchun Yang, appointed in Apr 2021, has a tenure of 3.67 years. directly owns 0.037% of the company’s shares, worth CN¥3.00M. The average tenure of the management team and the board of directors is 2.3 years and 3.6 years respectively.
Key information
Yongchun Yang
Chief executive officer
CN¥758.6k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Shares Lagging The Market But So Is The Business
Dec 03
With EPS Growth And More, Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Makes An Interesting Case
Aug 19Here's Why Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Has Caught The Eye Of Investors
May 21Shareholders Can Be Confident That Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings Are High Quality
Apr 25Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Mar 04Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Shares Fly 34% But Investors Aren't Buying For Growth
Mar 04CEO
Yongchun Yang (51 yo)
3.7yrs
Tenure
CN¥758,600
Compensation
Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3.7yrs | CN¥758.60k | 0.037% CN¥ 3.0m | |
| Deputy Chief Accountant | 1.9yrs | CN¥207.50k | 0.0044% CN¥ 356.7k | |
| Deputy General Manager | 1.5yrs | CN¥521.10k | 0.0070% CN¥ 570.5k | |
| Deputy General Manager | 5yrs | CN¥742.70k | 0.025% CN¥ 2.0m | |
| Deputy GM & Market Development Center | 2.8yrs | CN¥1.07m | 0.025% CN¥ 2.0m | |
| Deputy General Manager | 1.5yrs | CN¥637.00k | 0.018% CN¥ 1.5m | |
| Deputy General Manager | 2.8yrs | CN¥710.40k | 0.025% CN¥ 2.0m | |
| Secretary | less than a year | no data | no data |
2.3yrs
Average Tenure
47.5yo
Average Age
Experienced Management: 600557's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5yrs | CN¥758.60k | 0.037% CN¥ 3.0m | |
| Chairman | 24.1yrs | CN¥2.39m | 2.99% CN¥ 242.6m | |
| Vice Chairman of the Board | 8.3yrs | CN¥1.03m | 0.037% CN¥ 3.0m | |
| Supervisor | 1.5yrs | no data | no data | |
| Independent Director | 3.6yrs | CN¥100.00k | no data | |
| Independent Director | 5yrs | CN¥100.00k | no data | |
| Supervisor | 2.6yrs | no data | no data | |
| Director | 1.5yrs | CN¥641.10k | 0.0098% CN¥ 798.8k | |
| Supervisor | 1.5yrs | no data | no data |
3.6yrs
Average Tenure
51yo
Average Age
Experienced Board: 600557's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:13 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Kanion Pharmaceutical Co.,Ltd. is covered by 31 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Zhang | AJ Securities Co., Ltd |
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Changming He | BOCI Research Ltd. |